Case Study

Zydis® Bio Technology, Grazax® & Grastek®: Revolutionizing Allergy Therapy

Source: Catalent

ALK-Abelló is a global research-driven pharmaceutical company that focuses on the prevention, diagnosis and treatment of allergies. Before ALK-Abelló partnered with Catalent, all marketed allergen immunotherapies were delivered by injection,  resulting in a limited patient population and reduced patient adherence. Catalent worked with the client to apply Zydis® Fast Dissolve Technology to their therapy, bringing a vastly superior product to market. The overall result was a marked improvement  in patient tolerability, preference and compliance. This new technology has allowed ALKAbelló to deliver on their promise to improve the quality of life for allergy patients.


Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Bioprocess Online